LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Biogen and Eisai announced that China's National Medical Products Administration has approved the subcutaneous autoinjector formulation of LEQEMBI (lecanemab) for treating mild cognitive impairment and mild Alzheimer's dementia. This allows once-weekly at-home injections, offering a more convenient alternative to intravenous administration, and is …